Universal Beteiligungs und Servicegesellschaft mbH Invests $10.90 Million in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has acquired 87,796 shares of Jazz Pharmaceuticals, worth approximately $10.9 million, increasing its stake to 0.14% of the company.
• Various hedge funds have recently increased their investments in Jazz Pharmaceuticals, contributing to institutional investors owning 89.14% of the company's stock.
• Despite a recent sell-off by CEO Bruce C. Cozadd, insider ownership remains significant, at 4.30%, while Jazz Pharmaceuticals has a current market cap of $7.15 billion.

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The firm bought 87,796 shares of the specialty pharmaceutical company's stock, valued at approximately $10,900,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.14% of Jazz Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Quadrant Capital Group LLC lifted its position in Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after acquiring an additional 101 shares during the period. Elequin Capital LP lifted its position in Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after acquiring an additional 183 shares during the period. Allianz SE purchased a new position in Jazz Pharmaceuticals during the 4th quarter valued at about $29,000. Parallel Advisors LLC lifted its position in Jazz Pharmaceuticals by 85.6% during the 1st quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock valued at $32,000 after acquiring an additional 119 shares during the period. Finally, Spire Wealth Management lifted its position in Jazz Pharmaceuticals by 137.6% during the 1st quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock valued at $35,000 after acquiring an additional 161 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Seamus Mulligan acquired 100,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, May 9th. The stock was purchased at an average cost of $98.26 per share, with a total value of $9,826,000.00. Following the completion of the purchase, the director directly owned 100,000 shares in the company, valued at approximately $9,826,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $116.35, for a total transaction of $116,350.00. Following the completion of the sale, the chief executive officer directly owned 439,307 shares of the company's stock, valued at approximately $51,113,369.45. This trade represents a 0.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,500 shares of company stock valued at $277,930. Company insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ traded down $1.70 during trading hours on Tuesday, hitting $115.68. 91,957 shares of the company's stock traded hands, compared to its average volume of 963,358. The business's fifty day moving average price is $110.37 and its two-hundred day moving average price is $118.02. The company has a current ratio of 3.38, a quick ratio of 2.97 and a debt-to-equity ratio of 1.28. The firm has a market capitalization of $7.00 billion, a P/E ratio of 15.41, a P/E/G ratio of 5.69 and a beta of 0.32. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). The business had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The business's quarterly revenue was down .5% compared to the same quarter last year. During the same quarter last year, the firm posted $2.68 earnings per share. Equities research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on JAZZ. Piper Sandler reissued an "overweight" rating and set a $147.00 price target (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Needham & Company LLC reissued a "buy" rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 11th. Morgan Stanley decreased their target price on shares of Jazz Pharmaceuticals from $166.00 to $165.00 and set an "overweight" rating for the company in a report on Tuesday, July 22nd. Robert W. Baird decreased their target price on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Jazz Pharmaceuticals in a report on Tuesday, July 15th. They issued a "buy" rating and a $152.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $181.64.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.